<u>Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular</u>

<u>degeneration.</u>

Thomas H Julian[1,2], Johnathan Cooper-Knock[3], Stuart MacGregor[4], Hui Guo[5] Tariq Aslam[6], Eleanor

Sanderson[7], Graeme Black*[1,9], Panagiotis I Sergouniotis*[1,2,8,9],

1. Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology,

Medicine and Health, University of Manchester, Manchester, UK.

2. Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

3. Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN),

University of Sheffield, Sheffield, UK.

4. Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

5. Centre for Biostatistics, Division of Population Health, Health Services Research & Primary Care,

School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester,

Manchester, UK.

6. Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, School of Health

Sciences, The University of Manchester, Manchester, UK.

7. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.

8. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome

Genome Campus, Cambridge, UK.

9. Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS

Foundation Trust, Manchester, UK.

<u>*Corresponding authors:</u> Panagiotis Sergouniotis & Graeme Black

ABSTRACT:

Introduction:

Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialised world and

is projected to affect 288 million people worldwide by 2040. Aiming to identify causal factors for this common

disorder, we designed and applied a phenome-wide Mendelian randomisation (MR) approach to identify

therapeutic targets and avenues for future research.

Methods:

We evaluated the effect of 4,591 exposure traits on early AMD using univariable MR. Statistically significant

results were explored further using validation in an advanced AMD cohort, MR Bayesian model averaging

(MR BMA) and multivariable MR.

Results:

44 traits were found to be putatively causal for early AMD in univariable analysis. MR BMA of lipid traits

suggested a causal role for serum sphingomyelin (marginal inclusion probability=0.76, model averaged

causal effect=0.29). Univariable MR analysis supported roles for complement and immune cell traits. Serum

proteins were found to have significant relationships with AMD including S100-A5 (Odds ratio (OR)= 1.07,

p = 6.80E-06), cathepsin F (OR=1.10, p = 7.16E-05) and serine palmitoyltransferase 2 (OR= 0.86, p

value=1.00E-03).

Conclusions:

The results of this study support several putative causal factors in AMD and highlight avenues for future

clinical research.

INTRODUCTION:

Age-related macular degeneration (AMD) is a progressive multifactorial disorder that affects individuals who are ≥50 years old and is caused by the complex interplay of multiple genetic and environmental risk factors. Genome-wide association studies (GWAS) have identified AMD-implicated variants in at least 69 loci including important risk alleles in the 1q32 and 10q26 genomic regions (corresponding to the *CFH* - complement factor H – and *ARMS2/HTRA1* locus respectively) (Fritsche et al., 2016; Winkler et al., 2020). Other key risk factors include age, smoking, alcohol consumption and low dietary intake of antioxidants (carotenoids, zinc) (Chakravarthy et al., 2010).

AMD can be categorised according to severity (early, intermediate, or advanced) or based on the presence of neovascularization (neovascular or non-neovascular). Advanced AMD results in loss of central vision, often leading to severe visual impairment (Fleckenstein et al., 2021). Notably, AMD is a major cause of blindness in the elderly population and represents a substantial global burden that is expected to continue to grow into the future as an ageing population expands worldwide.

Mendelian randomization (MR) is a statistical approach that uses genetic variation to look for causal relationships between *exposures* (such as body mass index) and medically-relevant *outcomes* (such as risk of a specific disease) (Julian et al., 2021). MR is increasingly being used as it can overcome a major limitation of observational studies: unmeasured confounding(Sanderson et al., 2022). To minimise issues with certain types of confounding and to support causal inference statements, MR uses genetic variation as an "*instrument*" (i.e. as a variable that is associated with the exposure, independent of the confounders, and is not associated with the outcome, other than through the exposure). Its principles are based on Mendel's laws of segregation and independent assortment, which state that offspring inherit alleles randomly from their parents and randomly with respect to other locations in the genome (Julian et al., 2021). As a result, genetic variants that are related to an exposure of interest can be used to proxy the part of the exposure variable that is independent of possible confounding influences (e.g., from the environment and other traits). It is noted that analogies have been drawn between MR and randomised controlled trials with

these two approaches considered proximal in terms of hierarchy of evidence.(Julian et al., 2021) To date,

the use of MR approaches in the context of AMD has been limited, although these methods have been

successfully implemented to explore the relationship between AMD and a small number of traits including

lipids, thyroid function, CRP and complement factors.(Cipriani et al., 2021; Han et al., 2021, 2020b; Li et

al., 2022; Zuber et al., 2020)

In this study, we have developed a systematic, broad ('phenome-wide') MR analysis methodology which

serves to investigate the relationship between early AMD and several thousand exposure variables. Using

this approach, we report a set of traits that are robustly associated with genetic liability to AMD.

METHODS:

Data sources

Outcome data

Two AMD phenotypes were used as outcome measures in this study. The first was early AMD. The GWAS

summary statistics for this phenotype were taken from a meta-analysis by Winkler et al(Winkler et al., 2020).

This study focused on populations of European ancestries and used data from the ARIC, AugUR, CHS,

GHS, IAMDGC, KORA S4, LIFE-Adult NICOLA, UKBB and WHI studies (14,034 early AMD cases and

91,214 controls overall). A full description of how these studies classified participants as "early AMD" can

be found in Winkler et al(Winkler et al., 2020). The second phenotype that we studied was advanced AMD.

For this trait, we drew on GWAS summary statistics from a multiple trait analysis of GWAS (MTAG) study

by Han et al. (Han et al., 2020a). This meta-analysis also focused on individuals of European ancestries

and derived data from the IAMDGC 2013 (Fritsche et al., 2013) (17,181 cases and 60,074 controls) and

2016 (Fritsche et al., 2016) (16,144 advanced AMD cases and 17,832 controls) studies as well as the

GERA study (Kvale et al., 2015) (4,017 cases and 14,984 controls). The summary statistics produced in

this GWAS are primarily reflective of advanced AMD, but the GERA cohort included both advanced and

intermediate AMD cases. Notably, the MTAG approach is able to leverage the high genetic correlation

between the input phenotypes to detect genetic associations for advanced AMD.

Exposure data

In this study we performed a phenome-wide screen to make causal inferences on the role of an extensive range of traits in early and advanced AMD. To achieve this, we used both published and unpublished GWAS data from the IEU open GWAS database; these were accessible via the TwoSampleMR programme in R(Hemani et al., 2018). We included all European GWAS within the database but removed imaging phenotypes and eQTL data. In the early AMD analysis, we also excluded studies from the "ukb" and "met-d" batches as these are studies entirely derived from UK Biobank data and therefore had extensive population overlap with the early AMD GWAS (Sudlow et al., 2015). In the advanced AMD analysis, "ukb" and "met-d" batches were included. The early AMD analysis was conducted on 30/12/2021 and a total of 10,979 traits were considered for analysis. The advanced AMD analysis was conducted on 08/01/2022. On 26/01/2022 we added newly published 'finn-b' (n=2803) traits to our analysis in place of outdated finn-a traits (n=1489). As it is not possible to manually inspect the degree of population overlap for all traits prior to conducting the analysis, the degree of overlap for all significant traits was inspected after the analysis.

Instrument selection

In this study, we used a statistically driven approach to instrumental variable selection. In general, an arbitrary p-value threshold is set for the identification of appropriate single-nucleotide polymorphisms (SNPs) that are used as instrumental variables (referred to thereafter as instruments). A conventional value for selection of instruments is p=5E-08, but this can, in some cases, be problematic. For example, when the number of instruments exceeding this threshold is small, the analysis can be underpowered or, in certain cases of unbiased screens, the results can be inflated.(Boddy et al., 2022) With this in mind, we have set the p-value for instrument selection for each trait to the level where >5 instruments are available for each analysis. More specifically, for each trait, the analysis would first be conducted with a p-value for inclusion of 5E-8 and would sequentially increase by a factor of 10 each time until >5 eligible instruments are identified to a predefined maximum of p=5E-05. Final range of p values for inclusion was 5E-06 – 5E-08.

Proxies

Where an exposure instrument was not present in the outcome dataset, we sought to identify a suitable

proxy(Hartwig et al., 2016). In the early AMD analysis, we were able to achieve this by using the

TwoSampleMR software with a linkage disequilibrium R^2 value of 0.9 or above for identification of

SNPs(Purcell et al., 2007). For the advanced AMD phenotype we used data which was not derived from

the TwoSampleMR database and therefore the ensembl server was used to derive proxies(Cunningham

et al., 2022; Hemani et al., 2018).

Clumping

SNPs were clumped using a linkage disequilibrium R^2 value of 0.001 and a genetic distance cut-off of

10,000 kilo-bases.

Harmonisation

The effects of instruments on outcomes and exposures were harmonised in order to ensure that the beta

values (i.e. the regression analysis estimates of effect size) were signed with respect to the same alleles

(Hartwig et al., 2016). For palindromic alleles (i.e., alleles that are the same on the forward as on the reverse

strand), those with minor allele frequency (MAF) > 0.42 were omitted from the analysis in order to reduce

the risk of errors due to strand issues.

Removal of pleiotropic genetic variants and outliers

In addition to using a range of robust measures of scale (which quantify the statistical dispersion in a sample

of numerical data while resisting outliers) and quality control measures (as detailed below), we endeavoured

to remove pleiotropic instruments and outliers from the analysis. We operated this using a statistical

approach in which instruments which were more significant for the outcome than the exposure were

removed(Hemani et al., 2017). Radial MR, a simulation-based approach that detects outlying instruments

was also utilised(Bowden et al., 2018).

Causal inference

MR estimation was primarily performed using a multiplicative random effects (MRE) inverse variance

weighted (IVW) analysis. MRE IVW was selected over a fixed effects (FE) approach as it allows inclusion

of heterogeneous instruments, certain to occur within the breadth of this screen(Burgess et al., 2019). A

range of robust measures of scale were utilised to ensure the accuracy of the results and to cover for a

range of violations of the MR assumptions(Burgess et al., 2019). The robust measures selected were the

weighted median(Bowden et al., 2016a), Egger(Burgess and Thompson, 2017a), weighted mode(Hartwig

et al., 2017) and radial MR with modified second order weights(Bowden et al., 2018).

<u>Further quality control</u>

Instrument strength was determined using the F statistic (which tests the association between the

instruments and the exposure) (Burgess et al., 2011). F statistics were calculated against the final included

set of instruments. A mean F statistic >10 was considered sufficiently strong.

The Cochran's Q test was performed for each analysis. Cochran's Q is a measure of heterogeneity among

causal estimates and serves as an indicator of the presence of horizontal pleiotropy (which occurs when

an instrument exhibits effects on the outcome through pathways other than the exposure)(Bowden and

Holmes, 2019). It is important to note that a heterogeneous instrument is not necessarily invalid, but rather

calls for a primary assessment with an MRE IVW rather than an FE approach; this has been conducted as

standard throughout our analysis.

The MR-Egger intercept test was used to detect horizontal pleiotropy. When this occurs, the Egger

regression is robust to horizontal pleiotropy under the assumption that that pleiotropy is uncorrelated with

the association between the SNP and the exposure(Burgess and Thompson, 2017b). In this study,

assuming there is not demonstrable horizontal pleiotropy we do not utilise the Egger regression to

determine causal effect given its low power with a small number of SNPs (Bowden et al., 2015).

The I^2 statistic was calculated as a measure of heterogeneity between variant specific causal estimates. A

I^2 <0.9 indicates that Egger is more likely to be biased towards the null through violation of the `NO

Measurement Error' (NOME) assumption (Bowden et al., 2016b) .

Leave-one-out (LOO) cross-validation was performed for every analysis to determine if any particular SNP

was driving the significance of the causal estimates.

Management of duplicate traits/GWAS

As the GWAS database used contains multiple different GWAS studies for the certain traits, some

exposures were analysed on multiple occasions. Where this occurred, we considered the largest sample

size study to be the primary analysis. Where there were duplicate studies in the same population, we used

the study with the largest F statistic.

Identification of significant results

Before considering an MR result to be significant, the results of a range of causal inference and quality

control tests should be considered. Notably, it is not necessary for a study to find significance in all

measures to determine a true causal relationship. MR is a low power study type and as such an overly

conservative approach to multiple testing can be excessive(Burgess et al., 2019). However, in the context

of the present study we have chosen to consider the results of our early AMD phenome-wide screen as

significant only if they remained: significant after false discovery rate correction (FDR) in the MRE IVW;

nominally significant in weighted mode and weighted median; and nominally significant throughout the

leave-one-out analysis (IVW-MRE)(Benjamini and Hochberg, 1995). This conservative approach was

selected as a large number of phenotypes was considered and because we wanted to focus on high

confidence signals.

Where we identified causal traits for early AMD, we have additionally explored their relationship with

advanced AMD so as to ascertain whether these traits are also implicated in more severe disease. These

two AMD classifications are phenotypically distinct but are generally part of the same disease spectrum.

For this reason, where traits failed to replicate as causal factors in the advanced AMD dataset this would

not necessarily imply that they are not causal for early AMD. However, significance in both AMD traits

provides support for the detected causal links and evidence that a factor plays a role across the spectrum

of disease.

Multivariable mendelian randomisation

Multivariable MR was performed in circumstances where we aimed to estimate the effect of >1 closely

related or potentially confounding exposure traits.(Sanderson et al., 2019) P-values for the inclusion of

instruments for the exposures of interest were optimised to obtain sufficiently high (>10) conditional F-

statistics for reliable analysis (Sanderson et al., 2021). With this in mind, selection for exposures began at

$p>5E-08$ and where a trait's instruments had a conditional F-statistic <10 the p-value for selection was

reduced in an automated manner by factor of 10 until an F-statistic >10 was obtained in the final analysis.

We utilised the same clumping procedure as in our univariable MR analysis. Adjusted Cochran's Q statistics

were calculated, with a p-value of <0.05 indicating significant heterogeneity. Where the Cochran's Q

statistic indicated heterogeneity, a Q-statistic minimisation procedure was used to evaluate the causal

relationship, with testing both assuming high levels (0.9) and low levels (0.1) of phenotypic correlation

(Sanderson et al., 2021).

Two-sample multivariable Mendelian randomisation approach based on Bayesian model averaging

(MR-BMA)

Multivariable MR can be used to obtain effect estimates for a few (potentially related) traits, however it

cannot be directly applied when there are many traits to be considered. MR-BMA is a Bayesian approach

developed by Zuber et al *(Zuber et al., 2020)*. Their approach searches over sets of potential risk factors to

determine which are most likely to be causal risk factors.

Notably, Zuber *et al*. have previously performed an excellent analysis which considered the role of lipids

against an older AMD GWAS. This study served as the proof of the MR-BMA method and also

demonstrated that several lipid traits have causal roles in AMD. However, this analysis has two potential

limitations. First, it downweighed fatty acid traits through limiting composite traits for SNP identification to

HDL, LDL and triglycerides. Second, numerous lipids with a potential role in AMD were not included in the

analysis. For these reasons, we chose to conduct a more inclusive analysis with a slightly altered approach.

The following study design modifications were made compared to Zuber et al.(Zuber et al., 2020):

(1) Fatty acids were included as a composite trait (utilising GWAS data for serum fatty acids derived from

Nightingale Health 2020 listed in TwoSampleMR (Hemani et al., 2018)).

(2) All lipid and fatty acid measures in the Kettunen *et al* GWAS were considered as potential causal traits

(n=102 traits)(Kettunen et al., 2016);

(3) We utilised a more recent, early AMD GWAS(Winkler et al., 2020);

(4) In general, multivariable MR (of any sort) cannot produce reliable results where the included traits are

≥ 0.99 correlated with respect to the included instruments. For this reason, where two traits were highly

correlated, one was removed at random rather than manually selecting traits in a manner which risks

selection bias.

Additionally, we performed MR-BMA for immune cell and complement phenotypes. In this analysis

instruments were obtained at genome wide significance (5E-08) for every included exposure in the model

given that composite traits were not available and/or applicable. For the immune cell MR-BMA, all immune

traits in the Orru et al. GWAS present in TwoSampleMR were used as exposures(Orrù et al., 2020). In the

complement analysis, we used all complement traits available in both Sun et al. and Suhre et al. with the

exception of complement subfractions (Suhre et al., 2017; Sun et al., 2018).

For our MR-BMA analysis, the prior probability was set to 0.1 and the prior variance was set to 0.25. We

operated our stochastic search with 10,000 iterations and calculated empirical p-values with 100,000

permutations.

Presentation of effect sizes:

We aim to present effect sizes to enable readers to appraise the impact of putative risk factors. In

univariable MR, these are presented as OR per 1SD change in the exposure for continuous traits and beta

values for binary exposure traits. We present this way because odds ratios are uninformative for binary

exposure traits(Burgess and Labrecque, 2018). Similarly, beta values are not presented by all MR

authorities where an exposure variable is binary in nature and it's important to recognise that these are

indicative only. Multivariable MR effect sizes are presented as beta estimates irrespective of the nature of

the exposure variable, given that the role of Multivariable MR within this study is purely to identify

confounders.

MR-BMA effect sizes are presented in the form of MACE. The MACE is a conservative estimate of the

direct causal effect of an exposure on an outcome averaged across models. It should be noted that the

primary function of MR-BMA is to highlight the probable causal trait amongst a number of candidate causal

risk factors, and the authors of this study warn that the causal effects should be used to interpret direction

of effect but not necessarily as an absolute guide to magnitude (Zuber et al., 2020).

Software

R version 4.1.0.

TwoSampleMR version 0.5.6.

RadialMR version 1.0.

MVMR version 0.3

MR BMA code was sourced from https://github.com/verena-zuber/demo_AMD.

RESULTS:

Overview

Focusing on early AMD, we applied univariable MR analysis to a broad range of traits. Following careful

quality control, we sought to replicate significant results in an advanced AMD dataset and conducted further

analyses using multivariable MR and MR-BMA.

Overall, 4,591 traits were eligible for analysis. Among these, 44 were found to be putatively causal for early

AMD **(Table 1 and Supplementary Data 1 & 2)**. Most of these causal traits were serum lipoprotein

concentration and compositional measures (n=29). Other significant traits identified included immune cell

phenotypes (n=5), serum proteins (n=6) and disease phenotypes (n=4).

Trait Name	Odds Ratio	FDR Adjusted IVW P Value	MRE IVW Beta
Rheumatoid arthritis	NA	1.51E-06	0.08
Unswitched memory B cell %B cell	1.11	5.40E-05	0.10
CD62L- Dendritic Cell %Dendritic Cell	0.95	3.32E-02	-0.05
Effector Memory CD8+ T cell Absolute Count	1.08	1.79E-04	0.07
CD25 on IgD+ CD38- naive B cell	0.93	1.25E-04	-0.07
CD80 on plasmacytoid Dendritic Cell	0.96	1.63E-02	-0.04
Total cholesterol in IDL	0.80	6.48E-08	-0.22
Free cholesterol in IDL	0.80	5.51E-08	-0.22
Total lipids in IDL	0.79	3.35E-09	-0.23
Concentration of IDL particles	0.80	9.83E-09	-0.23
Phospholipids in IDL	0.79	1.86E-09	-0.23
Triglycerides in IDL	0.84	2.40E-07	-0.18
Total cholesterol in large LDL	0.83	9.85E-08	-0.19
Cholesterol esters in large VLDL	0.83	1.41E-07	-0.19
Free cholesterol in large LDL	0.83	7.07E-07	-0.18
Total lipids in large LDL	0.83	1.04E-07	-0.19
Concentration of large LDL particles	0.83	2.40E-07	-0.19
Phospholipids in large LDL	0.83	1.33E-06	-0.18
Cholesterol esters in large VLDL	0.82	6.55E-03	-0.20
18:2, linoleic acid (LA)	0.80	2.93E-07	-0.23
Total cholesterol in LDL	0.82	4.46E-08	-0.19
Total cholesterol in medium LDL	0.82	3.64E-09	-0.20
Cholesterol esters in medium LDL	0.82	5.93E-09	-0.20

Total lipids in medium LDL	0.81	3.35E-09	-0.21
Concentration of medium LDL particles	0.81	3.64E-09	-0.21
Phospholipids in medium LDL	0.81	1.86E-09	-0.21
Total cholesterol in small LDL	0.81	9.85E-08	-0.21
Total lipids in small LDL	0.81	2.65E-07	-0.21
Total cholesterol in small VLDL	0.85	2.54E-02	-0.16
Serum total cholesterol	0.77	3.67E-08	-0.26
Total phosphoglycerides	0.81	3.93E-03	-0.21
Triglycerides in very large HDL	0.87	4.37E-04	-0.14
Total lipids in very small VLDL	0.84	1.97E-03	-0.18
Concentration of very small VLDL particles	0.84	9.04E-04	-0.18
Phospholipids in very small VLDL	0.83	3.63E-03	-0.19
Interferon alpha-10	1.14	1.83E-02	0.13
Protein S100-A5	1.07	6.94E-04	0.07
Serine palmitoyltransferase 2	0.86	3.17E-02	-0.15
CD59 glycoprotein	1.10	1.77E-03	0.09
Complement factor H-related protein 5	1.09	9.30E-05	0.09
Cathepsin F	1.10	4.44E-03	0.10
Benign neoplasm: Skin, unspecified	NA	8.23E-03	0.07
Psychiatric diseases	NA	8.54E-05	-0.43
Mytonic disorders	NA	2.32E-02	0.00

Table 1.

This table contains data from analysis in an early AMD cohort. Only traits passing stringent

quality control described in the methods are listed. FDR = false discovery rate. IVW = inverse

variance weighted. MRE = multiplicative random effects. % = as a proportion of. NA = not

applicable, exposure traits of binary nature do not produce accurate odds ratios and as such beta

can be used to infer direction of effect but not necessarily magnitude.

Lipoprotein metabolism is linked to AMD risk

Univariable MR demonstrated significant causal relationships for 28 serum lipoprotein measures and 1

serum fatty acid concentration (18:2 linoleic acid) in early AMD (**Table 1**). These relationships were also

strongly supported by the results of an advanced AMD analysis (Kettunen et al., 2016) **(Supplementary**

data 3).

Serum metabolites are highly correlated traits, and the instruments for serum lipoprotein and fatty acid

measures in our study were demonstrably correlated **(Supplementary Figure 1)**. MR-BMA was used in

order to discern which traits were driving the causal relationships. In our initial analysis, two genetic variants

(rs11065987 [*BRAP*] and rs10455872 [*LPAL2*]) were found to be outliers in terms of Q statistic (Q statistic

13.84-15.71 and 6.79-10.46 respectively across models) **(Figures 1A-D)**. These SNPs were therefore

omitted and the analysis was re-run. In the subsequent analysis, no outlier SNPs were identified. The top

10 models ranked according to their posterior probability are presented in **Supplementary Data 4** and the

top 10 individual risk factors with respect to their marginal inclusion probability (MIP; defined as the sum of

the posterior probabilities over all the models where the risk factor is present) are shown in **Table 2**. The

MIPs of all traits included in our model are plotted in **Figure 2.** The top four traits with respect to their MIP

are serum sphingomyelins (MIP=0.76, model averaged causal effects (MACE) =0.29), triglycerides in IDL

(MIP=0.32, MACE= -0.16), free cholesterol (MIP=0.20, MACE=0.07) and phospholipids in very small VLDL

(MIP=0.63, MACE= -0.31). It is important to note that whilst MR-BMA functions to select the likely causal

risk factor amongst a set of candidate causal traits, it is not possible to achieve this with certainty. As such,

a definitive statement of causality for individual lipid traits cannot be obtained within the MR causal inference

framework.

Rank	Risk factor (Trait ID)	Marginal Inclusion	Average Effect	P value	FDR p value
1	Sphingomyelins (met-c-935)	0.76	0.30	2.40E-04	5.76E-03
2	Phospholipids in very small VLDL (met-c-955)	0.63	-0.31	1.00E-05	7.20E-04

3	Triglycerides in IDL (met-c-872)	0.32	-0.16	2.10E-04	5.76E-03
4	Free cholesterol (met-c-858)	0.20	0.07	2.83E-03	5.09E-02
5	Omega-3 fatty acids (met-c-855)	0.07	0.01	3.70E-02	2.34E-01
6	Free cholesterol in very large HDL (met-c-944)	0.07	0.01	2.74E-02	2.34E-01
7	Total lipids in very small VLDL (met-c-953)	0.06	-0.02	2.08E-02	2.34E-01
8	Cholesterol esters in medium VLDL (met-c-910)	0.05	0.01	3.66E-02	2.34E-01
9	Cholesterol esters in very large HDL (met-c-943)	0.05	0.01	4.87E-02	2.34E-01
10	Ratio of bisallylic groups to double bonds (met-c-844)	0.05	0.01	4.41E-02	2.34E-01

Table 2:

The lead causal traits identified by MR BMA of lipids in early AMD ranked according to their

marginal inclusion probability (MIP).

Figure 1A-D:

Plots generated for the top-ranking models in the first run of MR-BMA of lipid traits and early

AMD. Plots 2A and 2C are for Cook's distance and 2B and 2D of Cochran's Q. Outlier instruments

are annotated.

<u>Figure 2:</u>

A graph detailing the results of MR-BMA. Lipids are ranked according to their MIP. The four likely

true-causal traits are identified.

Serine palmitoyltransferase 2, an enzyme which catalyses the first committed step in sphingolipid

biosynthesis, was robustly associated with early AMD. The relevant odds ratio highlighted that genetic

liability to increasing serum enzyme levels is protective of AMD (**Table 1, Supplementary Data 1**, OR 0.86,

p = 1.00E-03). It is of interest that increasing serum levels of the associated enzyme serine

palmitoyltransferase 1 also appeared to be protective of early AMD in most measures (**Supplementary**

Data 2, OR 0.94, IVW p =2.00E-03, FDR IVW p= 0.05, weighted median p = 0.05, significant throughout

leave-one-out analysis). Serine palmitoyltransferase enzymes were not significantly related to risk of

advanced AMD **(Supplementary Data 3)**.

Reinforcing a causal role for complement

Increasing serum levels of the complement proteins CD59 glycoprotein (OR 1.10, IVW p= 2.04E-05) and

Complement factor H-related protein 5 (OR 1.10, IVW p = 7.70E-07) were found to be associated with

genetic liability to early AMD and passed multiple testing correction. Whilst Complement C4, Complement

factor B and Complement factor I were also related to early AMD risk at nominal level of significance, they

did not exceed the conservative criteria for causal inference imposed in this study with respect to robust

measures **(Supplementary Data 2)**. In subsequent advanced AMD analyses (**Supplementary Data 3**),

CD59 glycoprotein remained related to disease risk (OR 1.07, IVW p= 0.04, weighted median p=9.00E-04,

MR-Egger p=2.00E-03, weighted mode p =7.00E-03). Complement factor I reached a nominal level of

significance in the IVW measure (OR 0.95, p=0.05) but did not remain significant in robust tests. No other

complement measures nominally significant for early AMD were significantly related to advanced AMD.

Complement traits are correlated with one another, and as such MR BMA was attempted. In the initial

analysis, the relationship between complement proteins was strongly suggested to be driven by

complement factor H (Posterior probability=0.83, MIP=1.00, MIP=-0.68). However, rs2274700 (*CFHR3*,

Cook's distance 26.26-55.24 & Cochran's Q 0.87-2.12 across models) and rs10824796 (*MBL2*, Cook's

distance 0.13-9.93 & Cochran's Q 0.87-22.12 across models) were identified as outlier instruments and

therefore warranted removal from subsequent analysis. rs2274700, a genetic variant known to be

associated with AMD risk (Liao et al., 2016), represented the only instrument strongly associated with

complement factor H in the MR BMA analysis and as such its removal precluded an informative high-

throughput analysis of the complement cascade. Whilst it is clear that there is a causal relationship between

complement and AMD, we cannot comment with precision about the specific complement-related molecule

driving this.

Other immune traits have mixed protective and causal effects in AMD

Our screen identified other serum immune traits with potential causal roles in early AMD, with several of

these related to dendritic cell populations. These traits were Unswitched memory B cell as a proportion of

B cell (OR=1.11, p=4E-07), CD62L- Dendritic Cell as a proportion of Dendritic Cells (OR=0.95, p=1.22E-

03), Effector Memory CD8+ T cell Absolute Count (OR=0.95, p=1.56E-06), CD80 on plasmacytoid

Dendritic Cell (OR=0.96, p=4.20E-04) and interferon alpha 10 (OR=1.14, p=5.38E-04). Notably, numerous

immune traits were also found to be significantly associated with advanced AMD (**Supplementary Data 3)**.

As with lipids, these traits are highly correlated and it is not possible to confidently address which immune

cell trait is truly causal in a univariable analysis due to potential overlap in the genetic instruments for each

trait. MR BMA using the Orru et al. GWAS for the above immune traits was not possible due to too few

genetic variants strongly instrumenting across the exposure variables leading to a failure to construct a

meaningful model (Orrù et al., 2020). For this reason, we are unable to determine which of these specific

immune traits are driving the casual relationship between immune cell traits and AMD, though dendritic cell

traits dominate the univariable analysis.

Disease phenotypes are related to AMD risk:

There are four disease phenotypes/groups which were found to be significant at a level which satisfy the

criteria for causal inference defined in this study. These traits are rheumatoid arthritis (beta= 0.08, IVW

p=9.86E-09), psychiatric diseases (beta=-0.43,IVW p=6.88E-07), 'benign neoplasm: skin, unspecified'

(beta= 0.07 , IVW p= 1.76E-04) and myotonic disorders (beta=-0.003,IVW p= 7.49E-04). None of these

disorders were significant in advanced AMD. The very broad and non-specific definitions encapsulated in

the GWAS of benign skin neoplasms, psychiatric disease and myotonic disorder make it challenging to

apply further analyses within the scope of this study, but these may be interesting phenotypes for

exploration in future studies.

In univariable MR, rheumatoid arthritis was identified to be causally related to AMD as detailed above.

Multivariable MR with effector memory CD8+ T cell absolute count as a second exposure variable (utilising

a Q statistic minimisation procedure) demonstrated that the causal effect of rheumatoid arthritis was either

mediated by immune cells or underpinned by correlated pleiotropy (rheumatoid arthritis effect size: 0.03,

95% CI: -0.007-0.055; effector memory CD8+ T cell absolute count effect size 0.07, 95% CI: 0.001-0.19).

This finding persists in models assuming both very high (0.9) and low (0.1) phenotypic correlation.

With respect to the relationship between AMD and psychiatric disease, no reverse causation was identified

(p=0.31). More specific psychiatric traits which could be analysed were not significantly related to genetic

liability to early AMD **(Supplementary Data 2)**. We also explored an extensive range of psychiatric

disorders in the advanced AMD dataset and found no significant relationships **(Supplementary Data 3)**.

Due to the broad nature of this trait, and negative results for all disorders explored, it is not possible to

discern what the driving force behind the significant result for psychiatric disease. It appears probable that

psychiatric disease is a false positive result given that it lacks the supporting evidence of biological

plausibility, validation in an advanced AMD dataset, or supportive evidence through significance of other

similar traits in the early AMD analysis.

Serum cathepsin F and S100 proteins have a causal role in AMD

In addition to the four previously mentioned serum proteins causally associated with early AMD (**Table 1**,

Interferon alpha-10, CD59 glycoprotein, complement factor H-related protein and serine

palmitoyltransferase 2) a further two serum proteins were identified to have causal effects on AMD. These

are S100-A5 (OR 1.07, IVW p = 6.80E-06) and Cathepsin F (OR= 1.10, IVW p = 7.16E-05).

Serum cathepsin F (OR= 1.10, IVW p = 7.16E-05) was shown to be causally related to early AMD risk.

However, no other serum cathepsin group proteins produced significant results in early AMD and no

cathepsin group proteins were robustly significant in the advanced AMD analysis (although cathepsin S

and G have significant IVW values of p=1.71E-05 and p=0.001 respectively, **Supplementary data 3**).

Serum protein S100-A5 was demonstrated to be causal for AMD (OR 1.07, IVW p = 6.80E-06). Additionally,

protein S100-A13 was significantly related to early AMD risk in both IVW (OR=1.07, p=1.22E-05) and robust

measures (weighted median p=3.31E-05, weighted mode p=9.00E-04 , Egger p= 1.00E-03) but did not

remain significant throughout the leave-one-out analysis, suggesting the relationship for this particular

protein could be driven by a small number of influential variants. Whilst protein S100-A2 was nominally

significant in the IVW (p=0.04), it did not pass any robust measures. No S100 group proteins were

significantly related to advanced AMD risk **(Supplementary Data 3)**.

DISCUSSION:

In this study we used MR to advance our understanding of AMD pathogenesis. Our findings indicate

protective effects for serum VLDL and IDL compositional and concentration traits in AMD. Causal effects

for serum free cholesterol and sphingolipid metabolism were also highlighted. Notably, our results suggest

that increasing serum levels of sphingomyelins are causally linked to AMD and we report protective

relationships for specific enzymes implicated in sphingolipid biosynthesis. It is known that sphingolipids play

key roles in retinal physiology, and there is emerging evidence that some sphingolipids may play a role in

AMD pathogenesis.(Simon et al., 2021) Further, our findings are in keeping with those of a meta-analysis

of metabolomic studies which described pathway enrichment analysis suggesting a role for sphingolipid

metabolism in AMD (Hou et al., 2020). Whilst sphingomyelin itself has not previously been described as a

causative factor for AMD, other substances involved in sphingolipid metabolism (including ceramide, which

can serve as both a substrate for sphingomyelin synthesis or a product of sphingomyelin metabolism) have

been suggested as causal factors through regulation of retinal cell death, inflammation and

neovascularization (Simon et al., 2021). It is known that the balance of sphingolipids have crucial roles in

determining cell fates, and therefore it is interesting to note the contrasting effects of serine

palmitoyltransferase and sphingomyelin in this study(Taniguchi and Okazaki, 2020). Our study therefore

adds weight to the assertion that sphingolipids play a key role in AMD pathophysiology. Further study of

sphingolipid metabolism in AMD subjects is expected to provide important insights and to highlight potential

treatment targets.

Our MR findings support the well-documented assertion that complement plays a key role in AMD

pathogenesis.(Clark and Bishop, 2018; Jha et al., 2007; Sivaprasad and Chong, 2006). Whilst MR-BMA

was not feasible, univariable analysis supported roles for complement factor H related protein 5 and CD59

glycoprotein. A causal signal was obtained for Complement factor H-related protein 5, a finding in keeping

with recent studies highlighting the role of this and other factor-H-related proteins (FHR-1 to FHR4; all

involved in the regulation of complement factor C3b turnover) in AMD(Cipriani et al., 2021). An intriguing

observation was the apparently causal role of increasing serum levels of the complement-related CD59

glycoprotein (an inhibitor of membrane attack complex formation) in both early and advanced AMD. This

finding appears to be at odds with previous studies that investigated the impact of high levels of CD59 in a

model of AMD and found a potential therapeutic benefit (Cashman et al., 2011). The relationship between

systemic and local complement activation is poorly understood and studies have produced conflicting

results with respect to the roles of each in AMD(Clark and Bishop, 2018; Jha et al., 2007). It can therefore

be speculated that the superficially inconsistent results between our study and previous work on CD59

reflects the complicated relationship between serum and ocular CD59 expression.

It is interesting to note that a connection between complement and lipid accumulation has been proposed

in AMD. This includes evidence that dysregulation of the complement system results in lipid deposition both

systemically and in the retina, and metabolomic evidence that decreased VLDL and increased HDL are

associated with increased complement activation independent of AMD status(Armento et al., 2021). Given

our results, the relationship between VLDL and complement is an area warranting further study.

Cathepsins are a very diverse family of lysosomal proteases which play an important part in cellular

homeostasis by participating in antigen processing and degrade chemokines and proteases(Yadati et al.,

2020). Cathepsins are susceptible to age-related alterations, and have been linked to modulation of pro-

inflammatory signalling pathways. Additionally, cathepsins D and S have a direct role to play in the retina

in the degradation of photoreceptor outer segments. It has also been shown that homozygosity for variant

B cystatin C (an inhibitor of cysteine proteases) causes reduced secretion of mature cystatin C and is

associated with increased susceptibility to neovascular AMD(Turk et al., 2012; Zurdel et al., 2002). For

these reasons, it has been suggested that dysregulation of cathepsin activity may be a factor in AMD

pathophysiology. Here, we show data that suggests serum cathepsin F, a ubiquitously expressed cysteine

cathepsin, has a causal relationship with early AMD. The roles of specific cathepsins in AMD is an area

which has not yet been mechanistically explored.

S100 proteins act as intracellular regulators and extracellular signalling proteins. Intracellularly, S100

proteins have a wide range of roles including regulating proliferation, differentiation, apoptosis, calcium

homeostasis, metabolism and inflammation (Donato et al., 2013). Extracellular S100 proteins have

important roles in immunity and inflammation. Of the S100 protein family, serum S100-A5 is the only protein

to be robustly identified as a causal factor for AMD in our study. Whilst S100 proteins have received little

study in AMD thus far, the binding of S100B to RAGE and the subsequent increase in VEGF have previously

been shown to be linked to the development of AMD(Ma et al., 2007; Xia et al., 2017). S100-A5 is a protein

which has received very little study and as such its biological functions are mostly uncharacterised, but it is

known that it is involved in inflammation via the activation of RAGE(Wheeler and Harms, 2017). Whilst it

is outside the scope of this study to assert a mechanistic hypothesis for this finding, it seems likely that the

role of S100-A5 would be linked to the inflammatory processes.

For the most part, the present study has captured the known AMD risk factors. A notable omission however

is smoking, an accepted AMD risk factor. In this study, cigarettes smoked per day was associated with early

AMD at a nominal level of significance (IVW p=0.009) but was not significant with FDR or in robust

measures. This finding is most probably reflective of the underpowered nature of MR. Given the hypothesis

free nature of this study and the low power of MR, we have not commented on negative results as evidence

of a null relationship between environmental exposures and AMD.

In summary, this study has identified previously undescribed causal factors for AMD in addition to

reinforcing several previously suggested AMD risk factors. Future research will follow-up these causal

factors from a mechanistic perspective in order to open up avenues for therapeutic intervention.

Ethical approval

This study utilised publicly available data and no additional ethical approval is required.

AUTHOR CONTRIBUTIONS:

THJ, JCK, PIS, GB, HG and ES were involved in study conception and design. THJ and JCK performed

the statistical analysis. PIS, GB, GH, TA, SM and ES reviewed the methodology and statistical analysis. All

authors aided in interpretation of the results. All authors contributed to manuscript drafting and editing. All

authors approved the final manuscript. All authors meet the ICMJE authorship criteria.

ACKNOWLEDGEMENTS:

This project was funded by the NIHR and the Wellcome Institutional Strategic Support Fund for Causal

Inference. SM acknowledges Program Grant (1150144) and Senior Research Fellowship funding from the

Australian National Health and Medical Research Council (NHMRC).

COMPETING INTERESTS:

TA is involved on advisory boards and has received grants and speaker fees from Allergan, Novartis, Bayer,

Roche, Bausch and Lomb, Heidelberg, Topcon and Canon.

The remaining authors have no declarations.

DATA AVAILABILITY:

All data associated with this study are provided within the supplementary data.

REFERENCES:

Armento A, Ueffing M, Clark SJ. 2021. The complement system in age-related macular degeneration. *Cell*

Mol Life Sci **78**:4487–4505.

Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to

multiple testing. *J R Stat Soc* **57**:289–300.

Boddy S, Islam M, Moll T, Kurz J, Burrows D, McGown A, Bhargava A, Julian TH, Harvey C, Marshall

JNG, Hall BPC, Allen SP, Kenna KP, Sanderson E, Zhang S, Ramesh T, Snyder MP, Shaw PJ,

McDermott C, Cooper-Knock J. 2022. Unbiased metabolome screen leads to personalized medicine

strategy for amyotrophic lateral sclerosis. *Brain Commun* **4**. doi:10.1093/braincomms/fcac069

Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid instruments: effect

estimation and bias detection through Egger regression. *Int J Epidemiol* **44**:512–525.

Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016a. Consistent Estimation in Mendelian

Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*

40:304–314.

Bowden J, Del Greco M. F, Minelli C, Smith GD, Sheehan NA, Thompson JR. 2016b. Assessing the

suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger

regression: the role of the I2 statistic. *International Journal of Epidemiology*. doi:10.1093/ije/dyw220

Bowden J, Holmes MV. 2019. Meta-analysis and Mendelian randomization: A review. *Res Synth Methods*

10:486–496.

Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C, Davey Smith G. 2018.

Improving the visualization, interpretation and analysis of two-sample summary data Mendelian

randomization via the Radial plot and Radial regression. *Int J Epidemiol* **47**:1264–1278.

Burgess S, Labrecque JA. 2018. Mendelian randomization with a binary exposure variable: interpretation

and presentation of causal estimates. *European Journal of Epidemiology*. doi:10.1007/s10654-018-

0424-6

Burgess S, Smith GD, Davies NM, Dudbridge F, Gill D, Maria Glymour M, Hartwig FP, Holmes MV,

Minelli C, Relton CL, Theodoratou E. 2019. Guidelines for performing Mendelian randomization

investigations. *Wellcome Open Research* **4**. doi:10.12688/wellcomeopenres.15555.2

Burgess S, Thompson SG. 2017a. Interpreting findings from Mendelian randomization using the MR-

Egger method. *Eur J Epidemiol* **32**:377–389.

Burgess S, Thompson SG. 2017b. Erratum to: Interpreting findings from Mendelian randomization using

the MR-Egger method. *Eur J Epidemiol* **32**:391–392.

Burgess S, Thompson SG, CRP CHD Genetics Collaboration. 2011. Avoiding bias from weak instruments

in Mendelian randomization studies. *Int J Epidemiol* **40**:755–764.

Cashman SM, Ramo K, Kumar-Singh R. 2011. A Non Membrane-Targeted Human Soluble CD59

Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration. *PLoS*

ONE. doi:10.1371/journal.pone.0019078

Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P.

2010. Clinical risk factors for age-related macular degeneration: a systematic review and meta-

analysis. *BMC Ophthalmology*. doi:10.1186/1471-2415-10-31

Cipriani V, Tierney A, Griffiths JR, Zuber V, Sergouniotis PI, Yates JRW, Moore AT, Bishop PN, Clark SJ,

Unwin RD. 2021. Beyond factor H: The impact of genetic-risk variants for age-related macular

degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. *Am J Hum*

Genet **108**:1385–1400.

Clark SJ, Bishop PN. 2018. The eye as a complement dysregulation hotspot. *Semin Immunopathol*

40:65–74.

Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Austine-Orimoloye O, Azov

AG, Barnes I, Bennett R, Berry A, Bhai J, Bignell A, Billis K, Boddu S, Brooks L, Charkhchi M,

Cummins C, Da Rin Fioretto L, Davidson C, Dodiya K, Donaldson S, El Houdaigui B, El Naboulsi T,

Fatima R, Giron CG, Genez T, Martinez JG, Guijarro-Clarke C, Gymer A, Hardy M, Hollis Z, Hourlier

T, Hunt T, Juettemann T, Kaikala V, Kay M, Lavidas I, Le T, Lemos D, Marugán JC, Mohanan S,

Mushtaq A, Naven M, Ogeh DN, Parker A, Parton A, Perry M, Piližota I, Prosovetskaia I, Sakthivel

MP, Salam AIA, Schmitt BM, Schuilenburg H, Sheppard D, Pérez-Silva JG, Stark W, Steed E,

Sutinen K, Sukumaran R, Sumathipala D, Suner M-M, Szpak M, Thormann A, Tricomi FF, Urbina-

Gómez D, Veidenberg A, Walsh TA, Walts B, Willhoft N, Winterbottom A, Wass E, Chakiachvili M,

Flint B, Frankish A, Giorgetti S, Haggerty L, Hunt SE, IIsley GR, Loveland JE, Martin FJ, Moore B,

602  Mudge JM, Muffato M, Perry E, Ruffier M, Tate J, Thybert D, Trevanion SJ, Dyer S, Harrison PW,

603  Howe KL, Yates AD, Zerbino DR, Flicek P. 2022. Ensembl 2022. *Nucleic Acids Res* **50**:D988–D995.

604 Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. 2013. Functions of S100 proteins.

605  *Curr Mol Med* **13**:24–57.

606 Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong

607  WT, Chew EY. 2021. Age-related macular degeneration. *Nat Rev Dis Primers* **7**:31.

608 Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke

609  S, Igo RP Jr, Buitendijk GHS, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G,

610  Agarwal A, Armbrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN,

611  Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan C-C, Cheng C-Y,

612  Chew EY, Chin KA, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B,

613  Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ,

614  Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G,

615  Ioannidis JPA, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, N Keilhauer C, Khan JC, Kim

616  IK, Kiyohara Y, Klein BEK, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ,

617  Meitinger T, Mitchell P, Mohand-Saïd S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC,

618  Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJT, Peachey

619  NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel J-A,

620  Schaumberg DA, Scholl HPN, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G,

621  Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM,

622  Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L,

623  Vingerling JR, Vithana EN, Webster AR, Wichmann H-E, Winkler TW, Wong TY, Wright AF, Zelenika

624  D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R,

625  Baird PN, Gorin MB, Wang JJ, Klaver CCW, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates

626  JRW, Swaroop A, Weber BHF, Kubo M, Deangelis MM, Léveillard T, Thorsteinsdottir U, Haines JL,

627  Farrer LA, Heid IM, Abecasis GR, AMD Gene Consortium. 2013. Seven new loci associated with

628  age-related macular degeneration. *Nat Genet* **45**:433–9, 439e1–2.

629 Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Hebbring SJ,

Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HPN, Bala E, Lee KE, Hunter DJ, Sardell

RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YTE, Guymer RH,

Johnson MP, Jiang Y, Stanton CM, Buitendijk GHS, Zhan X, Kwong AM, Boleda A, Brooks M, Gieser

L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, Vote BJ, Liang HH,

Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable IJ, Craig JE, Kitchner TE,

Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Ferreyra H, Stark K, von Strachwitz

CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, Morgan DJ, Schu M, Ahn J, Silvestri G,

Tsironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, Curcio CA, Mohand-Saïd S, Sahel J-A,

Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverdhan SV, Grunin M, Hagbi-Levi S,

Campochiaro P, Katsanis N, Holz FG, Blond F, Blanché H, Deleuze J-F, Igo RP Jr, Truitt B, Peachey

NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser MA, Postel EA, Courtenay MD, Schwartz SG,

Kovach JL, Scott WK, Liew G, Tan AG, Gopinath B, Merriam JC, Smith RT, Khan JC, Shahid H,

Moore AT, McGrath JA, Laux R, Brantley MA Jr, Agarwal A, Ersoy L, Caramoy A, Langmann T,

Saksens NTM, de Jong EK, Hoyng CB, Cain MS, Richardson AJ, Martin TM, Blangero J, Weeks DE,

Dhillon B, van Duijn CM, Doheny KF, Romm J, Klaver CCW, Hayward C, Gorin MB, Klein ML, Baird

PN, den Hollander AI, Fauser S, Yates JRW, Allikmets R, Wang JJ, Schaumberg DA, Klein BEK,

Hagstrom SA, Chowers I, Lotery AJ, Léveillard T, Zhang K, Brilliant MH, Hewitt AW, Swaroop A,

Chew EY, Pericak-Vance MA, DeAngelis M, Stambolian D, Haines JL, Iyengar SK, Weber BHF,

Abecasis GR, Heid IM. 2016. A large genome-wide association study of age-related macular

degeneration highlights contributions of rare and common variants. *Nat Genet* **48**:134–143.

Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S. 2020a. Genome-wide meta-

analysis identifies novel loci associated with age-related macular degeneration. *J Hum Genet*

65:657–665.

Han X, Ong J-S, An J, Hewitt AW, Gharahkhani P, MacGregor S. 2020b. Using Mendelian randomization

to evaluate the causal relationship between serum C-reactive protein levels and age-related macular

degeneration. *Eur J Epidemiol* **35**:139–146.

Han X, Ong J-S, Hewitt AW, Gharahkhani P, MacGregor S. 2021. The effects of eight serum lipid

biomarkers on age-related macular degeneration risk: a Mendelian randomization study. *Int J*

Epidemiol **50**:325–336.

Hartwig FP, Davey Smith G, Bowden J. 2017. Robust inference in summary data Mendelian

randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**:1985–1998.

Hartwig FP, Davies NM, Hemani G, Davey Smith G. 2016. Two-sample Mendelian randomization:

avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *Int J*

Epidemiol **45**:1717–1726.

Hemani G, Tilling K, Davey Smith G. 2017. Orienting the causal relationship between imprecisely

measured traits using GWAS summary data. *PLoS Genet* **13**:e1007081.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J,

Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM,

Davey Smith G, Gaunt TR, Haycock PC. 2018. The MR-Base platform supports systematic causal

inference across the human phenome. *Elife* **7**. doi:10.7554/eLife.34408

Hou X-W, Wang Y, Pan C-W. 2020. Metabolomics in Age-Related Macular Degeneration: A Systematic

Review. *Invest Ophthalmol Vis Sci* **61**:13.

Jha P, Bora PS, Bora NS. 2007. The role of complement system in ocular diseases including uveitis and

macular degeneration. *Mol Immunol* **44**:3901–3908.

Julian TH, Boddy S, Islam M, Kurz J, Whittaker KJ, Moll T, Harvey C, Zhang S, Snyder MP, McDermott C,

Cooper-Knock J, Shaw PJ. 2021. A review of Mendelian randomization in amyotrophic lateral

sclerosis. *Brain*. doi:10.1093/brain/awab420

Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikäinen

L-P, Pirinen M, Pool R, Sarin A-P, Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Amin

N, Zeller T, Beekman M, Deelen J, van Dijk KW, Esko T, Hottenga J-J, van Leeuwen EM, Lehtimäki

T, Mihailov E, Rose RJ, de Craen AJM, Gieger C, Kähönen M, Perola M, Blankenberg S, Savolainen

MJ, Verhoeven A, Viikari J, Willemsen G, Boomsma DI, van Duijn CM, Eriksson J, Jula A, Järvelin M-

R, Kaprio J, Metspalu A, Raitakari O, Salomaa V, Slagboom PE, Waldenberger M, Ripatti S, Ala-

Korpela M. 2016. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel

systemic effects of LPA. *Nat Commun* **7**:11122.

Kvale MN, Hesselson S, Hoffmann TJ, Cao Y, Chan D, Connell S, Croen LA, Dispensa BP, Eshragh J,

Finn A, Gollub J, Iribarren C, Jorgenson E, Kushi LH, Lao R, Lu Y, Ludwig D, Mathauda GK, McGuire

WB, Mei G, Miles S, Mittman M, Patil M, Quesenberry CP Jr, Ranatunga D, Rowell S, Sadler M,

Sakoda LC, Shapero M, Shen L, Shenoy T, Smethurst D, Somkin CP, Van Den Eeden SK, Walter L,

Wan E, Webster T, Whitmer RA, Wong S, Zau C, Zhan Y, Schaefer C, Kwok P-Y, Risch N. 2015.

Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology

Research on Adult Health and Aging (GERA) Cohort. *Genetics* **200**:1051–1060.

Liao X, Lan C-J, Cheuk I-W-Y, Tan Q-Q. 2016. Four complement factor H gene polymorphisms in

association with AMD: A meta-analysis. *Arch Gerontol Geriatr* **64**:123–129.

Li X, Li H, Cheng J, Wang M, Zhong Y, Shi G, Yu A-Y. 2022. Causal Associations of Thyroid Function

and Age-Related Macular Degeneration: A Two-Sample Mendelian Randomization Study. *Am J

Ophthalmol* **239**:108–114.

Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM, Barile GR. 2007. RAGE ligand upregulation of

VEGF secretion in ARPE-19 cells. *Invest Ophthalmol Vis Sci* **48**:1355–1361.

Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, Sole G, Lai S, Dei M, Mulas A, Virdis F, Piras

MG, Lobina M, Marongiu M, Pitzalis M, Deidda F, Loizedda A, Onano S, Zoledziewska M, Sawcer S,

Devoto M, Gorospe M, Abecasis GR, Floris M, Pala M, Schlessinger D, Fiorillo E, Cucca F. 2020.

Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. *Nat Genet

52:1036–1045.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW,

Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based

linkage analyses. *Am J Hum Genet* **81**:559–575.

Sanderson E, Davey Smith G, Windmeijer F, Bowden J. 2019. An examination of multivariable Mendelian

randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* **48**:713–

727.

Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, Palmer T, Schooling CM,

Wallace C, Zhao Q, Davey Smith G. 2022. Mendelian randomization. *Nat Rev Methods Primers* **2**.

doi:10.1038/s43586-021-00092-5

Sanderson E, Spiller W, Bowden J. 2021. Testing and correcting for weak and pleiotropic instruments in

two-sample multivariable Mendelian randomization. *Stat Med* **40**:5434–5452.

Simon MV, Basu SK, Qaladize B, Grambergs R, Rotstein NP, Mandal N. 2021. Sphingolipids as critical

players in retinal physiology and pathology. *J Lipid Res* **62**:100037.

Sivaprasad S, Chong NV. 2006. The complement system and age-related macular degeneration. *Eye*

20:867–872.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M,

Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. 2015. UK

biobank: an open access resource for identifying the causes of a wide range of complex diseases of

middle and old age. *PLoS Med* **12**:e1001779.

Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, Sarwath H, Thareja G, Wahl A, DeLisle

RK, Gold L, Pezer M, Lauc G, El-Din Selim MA, Mook-Kanamori DO, Al-Dous EK, Mohamoud YA,

Malek J, Strauch K, Grallert H, Peters A, Kastenmüller G, Gieger C, Graumann J. 2017. Connecting

genetic risk to disease end points through the human blood plasma proteome. *Nat Commun*

8:14357.

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E,

Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N,

Spain SL, Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA,

Soranzo N, Suhre K, Paul DS, Fox CS, Plenge RM, Danesh J, Runz H, Butterworth AS. 2018.

Genomic atlas of the human plasma proteome. *Nature* **558**:73–79.

Taniguchi M, Okazaki T. 2020. Ceramide/sphingomyelin rheostat regulated by sphingomyelin synthases

and chronic diseases in Murine models. *J Lipid Atheroscler* **9**:380–405.

Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D. 2012. Cysteine cathepsins: from structure,

function and regulation to new frontiers. *Biochim Biophys Acta* **1824**:68–88.

Wheeler LC, Harms MJ. 2017. Human S100A5 binds Ca2+ and Cu2+ independently. *BMC Biophys* **10**:8.

Winkler TW, Grassmann F, Brandl C, Kiel C, Günther F, Strunz T, Weidner L, Zimmermann ME, Korb CA,

Poplawski A, Schuster AK, Müller-Nurasyid M, Peters A, Rauscher FG, Elze T, Horn K, Scholz M,

Cañadas-Garre M, McKnight AJ, Quinn N, Hogg RE, Küchenhoff H, Heid IM, Stark KJ, Weber BHF.

2020. Genome-wide association meta-analysis for early age-related macular degeneration highlights

novel loci and insights for advanced disease. *BMC Med Genomics* **13**:120.

Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. 2017. S100 Proteins As an Important Regulator of

Macrophage Inflammation. *Front Immunol* **8**:1908.

Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. 2020. The Ins and Outs of Cathepsins: Physiological

Function and Role in Disease Management. *Cells* **9**. doi:10.3390/cells9071679

Zuber V, Colijn JM, Klaver C, Burgess S. 2020. Selecting likely causal risk factors from high-throughput

experiments using multivariable Mendelian randomization. *Nat Commun* **11**:29.

Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G. 2002. CST3 genotype associated with exudative

age related macular degeneration. *Br J Ophthalmol* **86**:214–219.